Stephen Kanovsky
Director/Board Member at NEOGENOMICS, INC.
Net worth: 342 843 $ as of 29/04/2024
Stephen Kanovsky active positions
Companies | Position | Start | End |
---|---|---|---|
NEOGENOMICS, INC. | Director/Board Member | 18/07/2017 | - |
Independent Dir/Board Member | 18/07/2017 | - | |
GE Healthcare, Inc.
GE Healthcare, Inc. Medical SpecialtiesHealth Technology GE Healthcare, Inc. manufactures and distributes diagnostic imaging agents and radiopharmaceuticals for imaging modalities that are used in medical imaging procedures. It offers dyes that are used in magnetic-resonance-imaging procedures. The firm also manufactures medical diagnostic equipment including CT image machines. It develops healthcare technological solutions for medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery and biopharmaceutical manufacturing. The company was founded in 1994 and is headquartered in Princeton, NJ. | General Counsel | 31/08/2012 | - |
NeoGenomics Laboratories, Inc.
NeoGenomics Laboratories, Inc. Medical/Nursing ServicesHealth Services NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL. | Director/Board Member | - | - |
Career history of Stephen Kanovsky
Former positions of Stephen Kanovsky
Companies | Position | Start | End |
---|---|---|---|
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | General Counsel | - | - |
Merck Consumer Healthcare Group International
Merck Consumer Healthcare Group International Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, Merck Consumer Healthcare Group International manufactures pharmaceutical products for cancer. | Corporate Officer/Principal | - | - |
Archimedes Pharma Ltd.
Archimedes Pharma Ltd. Pharmaceuticals: MajorHealth Technology Archimedes Pharma Ltd. operates as a holding company with interests in pharmaceuticals. The company was founded by Richard Anthony de Souza, Charles Marchetti and Michael Clark on December 9, 2004 and is headquartered in London, the United Kingdom. | General Counsel | 22/11/2010 | - |
Training of Stephen Kanovsky
University of Pennsylvania | Undergraduate Degree |
Erivan K. Haub School of Business | Masters Business Admin |
Temple University Beasley School of Law | Graduate Degree |
Statistics
International
United States | 9 |
United Kingdom | 2 |
Operational
General Counsel | 3 |
Director/Board Member | 2 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 4 |
Health Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
NEOGENOMICS, INC. | Health Services |
Private companies | 5 |
---|---|
Archimedes Pharma Ltd.
Archimedes Pharma Ltd. Pharmaceuticals: MajorHealth Technology Archimedes Pharma Ltd. operates as a holding company with interests in pharmaceuticals. The company was founded by Richard Anthony de Souza, Charles Marchetti and Michael Clark on December 9, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
Merck Consumer Healthcare Group International
Merck Consumer Healthcare Group International Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, Merck Consumer Healthcare Group International manufactures pharmaceutical products for cancer. | Health Technology |
GE Healthcare, Inc.
GE Healthcare, Inc. Medical SpecialtiesHealth Technology GE Healthcare, Inc. manufactures and distributes diagnostic imaging agents and radiopharmaceuticals for imaging modalities that are used in medical imaging procedures. It offers dyes that are used in magnetic-resonance-imaging procedures. The firm also manufactures medical diagnostic equipment including CT image machines. It develops healthcare technological solutions for medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery and biopharmaceutical manufacturing. The company was founded in 1994 and is headquartered in Princeton, NJ. | Health Technology |
NeoGenomics Laboratories, Inc.
NeoGenomics Laboratories, Inc. Medical/Nursing ServicesHealth Services NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL. | Health Services |
- Stock Market
- Insiders
- Stephen Kanovsky
- Experience